The drug in question is called Aducanumab, or Aduhelm.
According to the latest study, the drug slows cognitive decline by 22%.
Experts say this isn't enough, but the FDA and Alzheimer's Association believe it's worth a shot.
The drug in question is called Aducanumab, or Aduhelm.
According to the latest study, the drug slows cognitive decline by 22%.
Experts say this isn't enough, but the FDA and Alzheimer's Association believe it's worth a shot.
It could be a game-changer for treating Alzheimer’s, but not all are convinced. Veuer’s Tony Spitz has the details.
Geoff Hart's doctor says he could be a good candidate to receive the new Alzheimer's drug.